Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milademetan PK and DDI with Itraconazole or Posaconazole in Healthy Subjects
NCT03614455Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of milademetan in Liposarcoma, acute myeloid leukemia (AML) and solid tumor (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Maximum plasma concentration at 168 hours and Area under the plasma concentration-time curve extrapolated to infinity at 168 hours. Started Jul 2018; status: completed.
02
Drugs
milademetan
03
Conditions
Liposarcomaacute myeloid leukemia (AML)solid tumor
Beyond the preview
Go deeper on NCT03614455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03614455.